

Durex Play™ Temptations Assorted Lubricants Premarket Approval 510(K)  
Application.

K060098

JUN - 8 2006

**Section VIII:**  
**Durex Play™ Temptations Assorted lubricants**  
**Premarket approval [510(k)] Application Summary.**

**Section VIII.1 Submitter Information**

SSL Americas  
3585 Engineering Drive  
Suite 200  
Norcross GA 30092-9214.  
Phone: 770-582-2222 Fax: 770-582-2233  
Contact Person: Chris Robinson, Controller Head of Regulatory Affairs, SSL  
Americas.  
Date of summary: 22<sup>nd</sup> December 2005.

**Section VIII.2 General Device Information**

Device trade Name: Durex Play™ Temptations Assorted lubricants.  
Device common name: Personal Lubricant  
Classification: Patient Lubricant

**Section VIII.3 Predicate devices.**

K-Y Jelly Personal lubricant (K955648)  
Astroglide (K935299)  
Durex Play™ Warmer lubricant (K042563)  
Durex Play™ Personal Lubricant (K032124)

**Section VIII.4 Device Description**

Durex Play™ Temptations Assorted personal lubricants are clear, colorless,  
water soluble personal lubricants.

The Tingle and Warming lubricants are already covered under K042958 and  
K042563 respectively.

Cont.

Durex Play™ Temptations Assorted Lubricants Premarket Approval 510(K) Application.

### **Section VIII.5 Intended Use**

Indications: Durex Play™ Temptations Assorted Lubricants are intended as moisturizers for vaginal dryness and personal lubrication of the vaginal entry to enhance condom use and to facilitate ease and comfort during intimate sexual activity.

### **Section VIII.6 Substantial Equivalence**

The product Durex Play™ Temptations Assorted Lubricants is substantially equivalent in intended use to K-Y Jelly, Astroglide and Durex Play™ personal lubricants. The formulations are very similar to the existing Durex Play™ formulations Durex Play™ and Durex Play Warmer™ All these products are sold Over-the-Counter and are condom compatible formulations.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
9200 Corporate Blvd.  
Rockville MD 20850

JUN - 8 2006

Mr. Chris Robinson  
Head of Regulatory Compliance  
SSL Americas, Inc.  
Office of Regulatory Affairs  
3585 Engineering Drive, Suite 200  
NORCROSS GA 30092-9214

Re: K060098

Trade/Device Name: Durex Play™ Temptations Assorted Personal Lubricant  
Regulation Number: 21 CFR 884.5300  
Regulation Name: Condom  
Regulatory Class: II  
Product Code: NUC  
Dated: May 11, 2006  
Received: May 15, 2006

Dear Mr. Robinson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.



*Protecting and Promoting Public Health*

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 894.xxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

